Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.34 CHF | -3.21% | -4.37% | -3.98% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Mar. 27 | Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.98% | 97.65M | |
+11.94% | 9.18B | |
-16.33% | 4.79B | |
+6.40% | 3.97B | |
+26.98% | 3.98B | |
+28.10% | 2.56B | |
-26.55% | 2.29B | |
-25.02% | 2.23B | |
+5.82% | 1.92B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SANN Stock
- News Santhera Pharmaceuticals Holding AG
- Transcript : Santhera Pharmaceuticals Holding AG, 2021 Earnings Call, Jun 10, 2022